Value Radar: Fresh Picks & Cboe Insights!

Value Radar: 10 Fresh Ideas + A Full Valuation Deep‑Dive on Cboe Global Markets (CBOE)

Date: November 13, 2025 (United States)

This research is educational, not investment advice. Every key assumption is sourced and shown so you can audit it.

10 new value candidates (quick scan)

  • Capital One (COF) — Discover merger approvals secured; closing in 2025 positions COF to own both a major issuing platform and a network, with consent orders/fines attached to Discover remediation. Potential long‑run cost/revenue synergies if integration is executed well. (reuters.com)
  • Cboe Global Markets (CBOE) — record Q3‑25 revenue/EPS; portfolio realignment to focus on derivatives and data (exiting listings in U.S./EU, pursuing sales of Australia/Canada). Raised FY25 organic growth outlook; lowered expense guide. Our pick for the deep‑dive below. (ir.cboe.com)
  • Travelers (TRV) — excellent Q3‑25: combined ratio 87.3%, strong core income; cycle discipline plus higher investment yields support mid‑teens ROE through the cycle. (investor.travelers.com)
  • Valero (VLO) — heavy cash returns in 2025, low net leverage; still levered to healthy U.S. distillate and export spreads with disciplined capex. (reuters.com)
  • Publicis (PUB.PA) — data scale-up via Lotame acquisition underpins targeted ads engine; still talking 4–5% organic growth for 2025, with cash redeployed to data/AI. (reuters.com)
  • Intercontinental Exchange (ICE) — resilient “all‑weather” model; record 2024 cash flow and strong 2025 results across exchanges, data, mortgages; steady capital returns. Good comp to CBOE. (ir.theice.com)
  • CME Group (CME) — top‑tier margins, durable interest‑rate/FX/energy complex; 3Q‑25 earnings solid; trades at a premium multiple among exchange peers. Useful comp for CBOE. (cmegroup.com)
  • Brookfield (BN) — diversified, asset‑heavy compounder; value tied to fee‑bearing capital growth and monetizations; watch rates and fundraising cadence. (Use as basket with BAM for “sum of parts.”)
  • Aflac (AFL) — capital‑light, high‑cash‑conversion protection business with strong buybacks/dividend; Japan FX exposure is the swing factor.
  • eBay (EBAY) — high free cash conversion, buyback‑heavy model; ad take‑rate tailwind; execution on GMV and verticals is key.

Now the full deep‑dive.


Cboe Global Markets (CBOE): full valuation deep‑dive

Why this is timely

  • Q3‑25 was a record quarter: net revenue $605.5M (+14% y/y), GAAP EPS $2.85 (+38%), adjusted EPS $2.67 (+20%). Management raised 2025 organic net revenue growth target to “low double‑digit to mid‑teens” and trimmed expense guidance. (ir.cboe.com)
  • Strategic realignment: initiating sales of Cboe Australia and Cboe Canada; discontinuing U.S./EU corporate listings; cost actions in some smaller lines. The company estimates roughly an 8–10% adjusted opex reduction at run‑rate (vs. 2025 guide baseline) with only ~3% net‑revenue impact. Focus is reinforced on proprietary derivatives (SPX/VIX), data, and core cash/spot markets. (ir.cboe.com)
  • Exclusive SPX options license with S&P Dow Jones runs through Dec 31, 2032 (exclusive) and 2033 (non‑exclusive), a key moat underpinning SPX/VIX economics. (ir.cboe.com)

Bottom line: This is a quality exchange franchise doubling down on its crown jewels (SPX/VIX and data). We test whether today’s price bakes in too much growth.


Business in one page

  • What they do: Exchange and clearing networks spanning U.S./EU cash equities and ETPs, U.S. and European derivatives (with flagship SPX options and VIX futures/options), global FX, and market‑data/analytics sold under the “Data Vantage” banner. Q3‑25: Derivatives +15% net revenue y/y; Cash & Spot +14%; Data Vantage +12%. (ir.cboe.com)
  • Cash engine: 2024 cash from operations (CFO) was $1.10B; capex on PP&E/leasehold ≈ $61M, implying very high free cash conversion. 2024 also included dividends ($249M) and buybacks ($205M). (sec.gov)
  • Shareholder returns: quarterly dividend raised to $0.72 in Q3 and maintained in Q4 2025; 15th consecutive year of increases. Shares outstanding ≈ 104–105M. (ir.cboe.com)

Moat pillars we underwrite:

  • Exclusivity on SPX and the VIX ecosystem (license through 2032/2033). (sec.gov)
  • Network effects and liquidity in index options; microstructure and product innovation (e.g., daily expiries in SPXW) sustain activity. (ww2.cboe.com)
  • Sticky, high‑margin data subscriptions (Data Vantage). (ir.cboe.com)

Cross‑checking the landscape (peers/positioning)

  • ICE: record multi‑year cash generation; 3Q‑25 net revenues $2.4B, adjusted EPS $1.71; margins near 59% adjusted; robust capital returns. (ir.theice.com)
  • CME: 3Q‑25 revenue $1.5B, net income $908M; premium valuation relative to peers (mid‑20s trailing P/E; high‑teens EV/EBITDA). (cmegroup.com)

These comps help frame multiples for sanity checks later.


Ground‑up valuation: FCFE DCF + comparables

We value equity directly using free cash flow to equity (FCFE) anchored in audited cash flow.

Key audited anchors (FY2024 unless noted):

  • CFO: $1,100.6M; PP&E/leasehold capex ≈ $60.9M. We treat Cboe as structurally low‑capex. (sec.gov)
  • Dividends: $249.4M (2024 actual), but note the dividend rose to $0.72/q in 2H25. (Dividends validate cash coverage; for FCFE we value pre‑distribution cash.) (sec.gov)
  • Shares: diluted weighted‑average ≈105.5M in 2024; spot outstanding ≈104.6M late‑2025. We use 105M for per‑share math. (sec.gov)
  • Structure: No large capex cycle in guidance; 2025 opex guide trimmed to $827–$842M with higher organic net‑revenue growth (“low double‑digit to mid‑teens”). We conservatively translate this into mid‑single‑digit FCFE growth after 2025. (ir.cboe.com)

How we map CFO to FCFE:

  • FCFE ≈ CFO – maintenance/growth capex – net working‑capital/other recurring items. For Cboe, CFO already includes interest/taxes and working capital swings (e.g., Section 31 timing). Using multi‑year context, a stable proxy is CFO minus PP&E capex. 2024 FCFE proxy ≈ $1,100.6M – $60.9M ≈ $1,040M. (sec.gov)

Model choices (documented):

  • Year‑1 FCFE base (2025E): we start at $1,020M–$1,150M to bracket “flat to modestly up” cash under the new focus/expense plan. Base case = $1,050M. Evidence: raised 2025 organic growth and lowered opex guide; capex remains light. (ir.cboe.com)
  • Near‑term FCFE growth (Years 1–5): 5–7% (base 6%). Rationale: derivatives and data growth, offset by mix/normalization risk and the realignment removing small revenue streams. (ir.cboe.com)
  • Terminal growth: 2.5–3.5% (base 3.0%), consistent with global GDP/inflation and exchange moats.
  • Cost of equity (discount rate): 8.0–9.0% (base 8.5%), reflecting large‑cap, cash‑rich, oligopolistic market‑infra risk. Cross‑check to peer quality and rate backdrop. (ir.theice.com)

DCF math (base case)

  • FCFE(2025E) = $1,050M; grow at 6% for 5 years; terminal g = 3.0%; r = 8.5%.
  • PV of Years 1–5 ≈ $4.8B; PV of terminal value ≈ $17.0B; Equity value ≈ $21.8B.
  • Per share (105M) ≈ $208.

We then test two more scenarios:

  • Upside case: FCFE(2025E) = $1,150M; Years 1–5 growth 7%; g = 3.5%; r = 8.0% → equity ≈ $27–28B → ≈ $255–$265/sh.
  • Downside case: FCFE(2025E) = $1,020M; Years 1–5 growth 4%; g = 2.5%; r = 9.0% → equity ≈ $18–19B → ≈ $170–$180/sh.

Key sensitivities (what moves value most):

  1. FCFE level (SPX/VIX activity and pricing; data growth)
  2. Discount rate (macro/risk premia)
  3. Terminal growth (license/competition outcomes post‑2032)

All inputs above are either audited/quantified (CFO, capex, shares), or tied to the company’s 2025 outlook that we translate conservatively to cash growth. (sec.gov)

Comparable‑multiples checks

  • Trailing P/E: CME ≈ mid‑20s; ICE typically high‑teens/low‑20s; CBOE’s trailing P/E around mid‑20s at recent prices. On a peer‑band of ~20–26x and an annualized EPS run‑rate near ~$10–$11 (Q3‑25 GAAP EPS was $2.85), an implied range is roughly $200–$275 before any premium/discount for growth mix. (cmegroup.com)
  • EV/EBITDA: CME ~19x TTM; ICE often mid‑ to high‑teens given more diversification; this suggests a quality exchange cohort trading ~16–20x EV/EBITDA. CBOE’s mix shift toward derivatives/data argues for the upper half, but not a peak premium to CME. (valueinvesting.io)

Multiples sanity aligns with our DCF band.


What could change the thesis?

Upside levers

  • Sustained high SPX/VIX volumes, daily expiries adoption, and new product innovation lifting capture rates. (ww2.cboe.com)
  • Data Vantage monetization (pricing, new feeds/analytics) and expense discipline ahead of plan. (ir.cboe.com)
  • Portfolio sales (Australia/Canada) at attractive multiples with minimal earnings drag. (ir.cboe.com)

Downside risks

  • License/key‑product concentration: SPX/VIX drive outsized economics; any license dispute or adverse renegotiation beyond 2032 would matter. (sec.gov)
  • Lower realized volatility for extended periods (VIX complex softness) or competitive inroads in non‑proprietary options.
  • Regulatory or fee‑structure changes affecting data or market‑access pricing.

Roadmap to value creation (12–24 months)

  1. Execute the portfolio realignment
    • Close asset sales (Australia/Canada), wind down low‑ROI listings, and capture the guided 8–10% opex reduction run‑rate vs. 2025 baseline. Track disclosure on revenue/EBITDA mix post‑actions. (ir.cboe.com)
  2. Reinforce the derivatives flywheel
    • Keep expanding SPX expiries, micro/mini contracts (e.g., XSP), education, and market‑maker support to deepen liquidity. (ww2.cboe.com)
  3. Grow Data Vantage
    • Hit the upgraded 2025 organic growth range and articulate 2026–27 pricing/mix ambitions to justify a stickier multiple. (ir.cboe.com)

Step‑by‑step audit trail (what we did and why)

  1. Anchored FCFE to audited CFO ($1,100.6M, 2024) and capex ($60.9M) from the 2024 10‑K; validated cash returns (dividends/buybacks). (sec.gov)
  2. Incorporated 2025 guidance shifts (raised organic revenue growth; lowered opex) and strategy changes (asset sales, listings exit) from the Oct 31, 2025 release; mapped these to conservative 2025 FCFE and 5‑year growth. (ir.cboe.com)
  3. Confirmed moat duration by checking SPX/VIX licensing terms to 2032/2033. (sec.gov)
  4. Cross‑checked comp bands using ICE/CME recent results and market multiples to sanity‑check DCF outputs. (ir.theice.com)

Verdict and valuation range

  • Valuation range: $170–$265 per share, with a base DCF around ~$208.
  • What the range means: At today’s typical trading levels for CBOE (late‑October snapshot near ~$246), the stock embeds optimistic assumptions on FCFE growth and/or a lower discount rate than our base. That’s not “expensive at any price,” but risk‑reward skews to execution‑dependent upside. (stockanalysis.com)
  • Recommendation: Quality compounder, but for strict value, prefer an entry below ~$210 (a margin of safety to our base DCF and inside peer P/E bands). Accumulate more aggressively ≤$190 if volatility/volumes temporarily compress and price follows.
  • What would change our view to “buy at market”: evidence that post‑realignment FCFE can sustain ≥$1.2–$1.3B with 6–8% CAGR and that data growth tracks high‑single/low‑double digits for 2026–27.

Appendix: quick peer markers you can monitor

  • ICE: record 2024 CFO ~$4.6B; 3Q‑25 adjusted EPS $1.71; adj op margin ~59%. If ICE’s multiple expands on mortgage/data growth, it may lift the sector. (ir.theice.com)
  • CME: 3Q‑25 EPS $2.49 GAAP ($2.68 adj); trades at a consistent premium multiple (mid‑20s PE; high‑teens EV/EBITDA). Useful ceiling for CBOE’s multiple. (cmegroup.com)

If you want, I can share a compact spreadsheet so you can flex FCFE, discount rate, and terminal growth and see per‑share values across scenarios.